Benzhydrocodone

Benzhydrocodone
Clinical data
Routes of
administration
Oral
Identifiers
Synonyms KP201
CAS Number
ChemSpider
KEGG
Chemical and physical data
Formula C25H25NO4
Molar mass 403.470
3D model (JSmol)

Benzhydrocodone (INN) (contracted from benzoate-hydrocodone) is a opioid prodrug of the morphinan class. Its chemical structure consists of hydrocodone coupled with benzoic acid. Benzhydrocodone itself is inactive and acts as a prodrug to hydrocodone upon cleavage of the benzoate portion of the molecule.[1]

It is designed to be an opioid analgesic with a low chance of recreational use.[2]

Created by a biopharmaceutical company in Coralville, Iowa. President and CEO, Travis Mickle, believes the molecular-based approach to abuse deterrent may be more effective than many formulation-based approaches.[3]

References

  1. KemPharm, Inc. (June 11, 2013). "KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201" (Press release). North Liberty, Iowa: PR Newswire. Retrieved February 8, 2015.
  2. Lavitt, John (June 12, 2014). "New Abuse-Resistant Opioid Receives $60 Million Backing". http://thefix.com/. The Fix. Retrieved February 8, 2015. External link in |website= (help)
  3. "KP201/APAP". http://www.kempharm.com/. Retrieved April 20, 2015. External link in |website= (help)



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.